|393.04||-7.00||-1.75%||Vol 381.17K||1Y Perf 21.17%|
|Apr 19th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||456.39||Analyst Rating||Strong Buy 1.45|
|Potential %||16.12||Finscreener Ranking||★★★★ 53.92|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★ 51.20|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 77.04|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||38.01B||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||58.04||Earnings Date||29th Apr 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|10 Years||2 270.57%|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||29th Apr 2021|
|Estimated EPS Next Report||0.31|
|EPS Growth Next 5 Years %||17.80|
|Avg. Weekly Volume||465.61K|
|Avg. Monthly Volume||622.57K|
|Avg. Quarterly Volume||773.38K|
DexCom Inc. (NASDAQ: DXCM) stock closed at 393.04 per share at the end of the most recent trading day (a -1.75% change compared to the prior day closing price) with a volume of 389.74K shares and market capitalization of 38.01B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 6400 people. DexCom Inc. CEO is Kevin R. Sayer.
The one-year performance of DexCom Inc. stock is 21.17%, while year-to-date (YTD) performance is 6.31%. DXCM stock has a five-year performance of 486.1%. Its 52-week range is between 305.63 and 456.23, which gives DXCM stock a 52-week price range ratio of 58.04%
DexCom Inc. currently has a PE ratio of 79.20, a price-to-book (PB) ratio of 21.18, a price-to-sale (PS) ratio of 24.98, a price to cashflow ratio of 82.00, a PEG ratio of 2.32, a ROA of 14.31%, a ROC of 10.89% and a ROE of 35.42%. The company’s profit margin is 31.91%, its EBITDA margin is 19.60%, and its revenue ttm is $1.52 Billion , which makes it $15.73 revenue per share.
Of the last four earnings reports from DexCom Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.31 for the next earnings report. DexCom Inc.’s next earnings report date is 29th Apr 2021.
The consensus rating of Wall Street analysts for DexCom Inc. is Strong Buy (1.45), with a target price of $456.39, which is +16.12% compared to the current price. The earnings rating for DexCom Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
DexCom Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
DexCom Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 16.45, ATR14 : 14.10, CCI20 : 109.02, Chaikin Money Flow : 0.31, MACD : 0.52, Money Flow Index : 80.74, ROC : 9.36, RSI : 45.71, STOCH (14,3) : 85.74, STOCH RSI : 0.61, UO : 70.78, Williams %R : -14.26), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of DexCom Inc. in the last 12-months were: Andrew K. Balo (Sold 21 674 shares of value $8 231 009 ), Barbara E. Kahn (Sold 9 800 shares of value $3 732 696 ), Bridgette P. Heller (Sold 375 shares of value $133 744 ), Donald Abbey (Sold 25 071 shares of value $10 008 614 ), Jake Leach (Sold 28 342 shares of value $10 687 167 ), Jereme M. Sylvain (Sold 3 662 shares of value $1 360 174 ), Kevin R. Sayer (Sold 174 247 shares of value $62 940 042 ), Mark G. Foletta (Sold 3 000 shares of value $1 132 274 ), Nicholas Augustinos (Sold 9 375 shares of value $3 574 635 ), Patrick Michael Murphy (Sold 20 513 shares of value $7 592 094 ), Quentin S. Blackford (Sold 31 588 shares of value $12 374 549 ), Richard B. Doubleday (Sold 28 505 shares of value $10 883 605 ), Richard Doubleday (Sold 16 102 shares of value $6 285 462 ), Shelly Ramasamy Selvaraj (Sold 12 121 shares of value $4 696 524 ), Steven R. Altman (Sold 42 000 shares of value $16 850 599 ), Steven R. Pacelli (Sold 50 473 shares of value $19 455 781 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.